[
    [
        {
            "time": "2018-01-02",
            "original_text": "Don't freak out about today's selloff, but retail is still in trouble",
            "features": {
                "keywords": [
                    "selloff",
                    "retail",
                    "trouble"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "retail"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Don't freak out about today's selloff, but retail is still in trouble",
                "Correlation": 6,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-09-30",
            "original_text": "Top Performing ETFs of the Third Quarter",
            "features": {
                "keywords": [
                    "ETFs",
                    "Third Quarter",
                    "Performing"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 4,
                "Duration": 8,
                "Entity_Density": 1,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-10-01",
            "original_text": "J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion",
            "features": {
                "keywords": [
                    "J&J",
                    "Arrowhead",
                    "gene-silencing",
                    "drug deal",
                    "$3.7 billion"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-01",
            "original_text": "7 Healthcare Stocks to Buy Right Now",
            "features": {
                "keywords": [
                    "Healthcare Stocks",
                    "Buy",
                    "Right Now"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-10-01",
            "original_text": "Seattle Genetics: Impact of the Cascadian Acquisition",
            "features": {
                "keywords": [
                    "Seattle Genetics",
                    "Cascadian",
                    "Acquisition"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-01",
            "original_text": "Stocks - Apple, Amazon Fall in Pre-market; Barnes & Noble Surges",
            "features": {
                "keywords": [
                    "Apple",
                    "Amazon",
                    "Pre-market",
                    "Barnes & Noble",
                    "Surges"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "technology",
                    "retail"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 2,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-10-01",
            "original_text": "J&J's Phase III Data Shows Switch to its HIV Drug Beneficial",
            "features": {
                "keywords": [
                    "J&J",
                    "Phase III",
                    "HIV Drug",
                    "Beneficial"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-01",
            "original_text": "Health-Care Stocks’ High Valuations May Not Be a Problem",
            "features": {
                "keywords": [
                    "Health-Care Stocks",
                    "High Valuations",
                    "Problem"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 4,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-10-01",
            "original_text": "Arrowhead Announces $3.7B License Agreement With Janssen For Gene-Silencing Drug",
            "features": {
                "keywords": [
                    "Arrowhead",
                    "License Agreement",
                    "Janssen",
                    "Gene-Silencing Drug",
                    "$3.7B"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-01",
            "original_text": "UPDATE: Arrowhead Pharma stock surges 19% on news of $3.7 billion license agreement with Janssen",
            "features": {
                "keywords": [
                    "Arrowhead Pharma",
                    "stock",
                    "surges",
                    "19%",
                    "$3.7 billion",
                    "license agreement",
                    "Janssen"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-01",
            "original_text": "Eli Lilly’s Stock Performance and Estimates for Q3 2018",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Stock Performance",
                    "Q3 2018"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-01",
            "original_text": "Moody's: Biosimilars a growing challenge biotech drugs, with European market developing more quickly than the US",
            "features": {
                "keywords": [
                    "Moody's",
                    "Biosimilars",
                    "challenge",
                    "biotech drugs",
                    "European market",
                    "US"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]